The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Oral azacitidine plus CHOP for frontline PTCL treatment
Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, discusses a Phase II study (NCT03542266) aiming to evaluate the efficacy and safety of combined azacitidine and CHOP as initial treatment in peripheral T-cell lymphoma (PTCL) patients. The findings demonstrated that the addition of oral azacitidine to CHOP as initial therapy is feasible, safe, and induces high response rates in PTCL-TFH patients in particular. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
